1,012 reports of this reaction
2.3% of all BIMATOPROST reports
#7 most reported adverse reaction
ERYTHEMA OF EYELID is the #7 most commonly reported adverse reaction for BIMATOPROST, manufactured by Allergan, Inc.. There are 1,012 FDA adverse event reports linking BIMATOPROST to ERYTHEMA OF EYELID. This represents approximately 2.3% of all 44,865 adverse event reports for this drug.
Patients taking BIMATOPROST who experience erythema of eyelid should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ERYTHEMA OF EYELID is a less commonly reported adverse event for BIMATOPROST, but still significant enough to appear in the safety profile.
In addition to erythema of eyelid, the following adverse reactions have been reported for BIMATOPROST:
The following drugs have also been linked to erythema of eyelid in FDA adverse event reports:
ERYTHEMA OF EYELID has been reported as an adverse event in 1,012 FDA reports for BIMATOPROST. This does not prove causation, but indicates an association observed in post-market surveillance data.
ERYTHEMA OF EYELID accounts for approximately 2.3% of all adverse event reports for BIMATOPROST, making it a notable side effect.
If you experience erythema of eyelid while taking BIMATOPROST, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.